Comparative efficacy and safety of low dose vs. standard-dose immune checkpoint inhibitors: A systematic review and meta-analysis
Abstract
Several studies have reported that low-dose of programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors is effective. However, it is unknown whether the efficacy of low dose is as effective as standard dose. We compared the efficacy of PD-1/PD-L1 inhibitor at different doses as a single agent for patients with solid tumors. We searched published clinical trials with the clinical outcomes of PD-1/PD-L1 inhibitor until December 1, 2024. The low dose is defined as lower than the dose approved by FDA. A total of 1,084 patients from 14 studies were included in the analysis. The pooled analysis of seven studies demonstrated no significant difference in overall survival (OS) between the low dose and standard dose of PD-1/PD-L1 inhibitor. Safety evaluations from five studies indicated no significant differences in adverse events (AEs). Our study indicated that low dose of PD-1/PD-L1 inhibitor as monotherapy can provide comparable efficacy and safety to standard dose in patients with solid tumors.
Related
- Circulating tumor DNA for prognosis in hematologic malignancies receiving immune checkpoint inhibitors or chimeric antigen receptor T-cell therapy: a systematic review and meta-analysis
- Association between antibiotic exposure and survival outcomes in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
- Adjusted Comparative Treatment Persistence of IL-23p19 Versus IL-17 Pathway Inhibitors in Adults With Plaque Psoriasis: A Systematic Review and Exploratory Meta-analysis of Real-World Time-to-Discontinuation Estimates
- Commentary: Hemophagocytic lymphohistiocytosis induced by immune checkpoint inhibitors: observations and proposed clinical management
- Immune checkpoint inhibitors and the inflammatory dysregulation: decoding cutaneous and gastrointestinal immune-related adverse events for the allergist and immunologist
BibTeX
@article{wu2026comparative,
title = {{Comparative efficacy and safety of low dose vs. standard-dose immune checkpoint inhibitors: A systematic review and meta-analysis}},
author = {Yuan Wu and Jianing Qin and Xin Jin and Yu Qian},
journal = {iScience},
year = {2026},
month = oct,
doi = {10.1016/j.isci.2026.117685},
url = {https://www.cell.com/iscience/fulltext/S2589-0042(26)03066-X},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Comparative efficacy and safety of low dose vs. standard-dose immune checkpoint inhibitors: A systematic review and meta-analysis
AU - Yuan Wu
AU - Jianing Qin
AU - Xin Jin
AU - Yu Qian
PY - 2026
DA - 2026/10/21
JO - iScience
DO - 10.1016/j.isci.2026.117685
UR - https://www.cell.com/iscience/fulltext/S2589-0042(26)03066-X
AB - Several studies have reported that low-dose of programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors is effective. However, it is unknown whether the efficacy of low dose is as effective as standard dose. We compared the efficacy of PD-1/PD-L1 inhibitor at different doses as a single agent for patients with solid tumors. We searched published clinical trials with the clinical outcomes of PD-1/PD-L1 inhibitor until December 1, 2024. The low dose is defined as lower than the dose approved by FDA. A total of 1,084 patients from 14 studies were included in the analysis. The pooled analysis of seven studies demonstrated no significant difference in overall survival (OS) between the low dose and standard dose of PD-1/PD-L1 inhibitor. Safety evaluations from five studies indicated no significant differences in adverse events (AEs). Our study indicated that low dose of PD-1/PD-L1 inhibitor as monotherapy can provide comparable efficacy and safety to standard dose in patients with solid tumors.
SN - 2589-0042
ER -